Literature DB >> 29877097

A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Wolfgang M Kuebler1,2,3,4, Mark R Nicolls5, Andrea Olschewski6,7, Kohtaro Abe8, Marlene Rabinovitch9, Duncan Stewart10, Stephen Y Chan11, Nicholas W Morrell12, Stephen L Archer13, Edda Spiekerkoetter5.   

Abstract

The following review summarizes the pro-con debate about current controversies regarding the pathogenesis of pulmonary arterial hypertension (PAH) that took place at the American Thoracic Society Conference in May 2017. Leaders in the field of PAH research discussed the importance of the immune system, the role of hemodynamic stress and endothelial apoptosis, as well as bone morphogenetic protein receptor-2 signaling in PAH pathogenesis. Whereas this summary does not intend to resolve obvious conflicts in opinion, we hope that the presented arguments entice further discussions and draw a new generation of enthusiastic researchers into this vibrant field of science to bridge existing gaps for a better understanding and therapy of this fatal disease.

Entities:  

Mesh:

Year:  2018        PMID: 29877097      PMCID: PMC6230875          DOI: 10.1152/ajplung.00150.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  126 in total

Review 1.  Regulatory T cells and pulmonary hypertension.

Authors:  Rasa Tamosiuniene; Mark R Nicolls
Journal:  Trends Cardiovasc Med       Date:  2011-08       Impact factor: 6.677

Review 2.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

3.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

4.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

5.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

6.  Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.

Authors:  James West; Karen Fagan; Wolfgang Steudel; Brian Fouty; Kirk Lane; Julie Harral; Marloes Hoedt-Miller; Yuji Tada; John Ozimek; Rubin Tuder; David M Rodman
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

7.  TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Authors:  Liam A Hurst; Benjamin J Dunmore; Lu Long; Alexi Crosby; Rafia Al-Lamki; John Deighton; Mark Southwood; Xudong Yang; Marko Z Nikolic; Blanca Herrera; Gareth J Inman; John R Bradley; Amer A Rana; Paul D Upton; Nicholas W Morrell
Journal:  Nat Commun       Date:  2017-01-13       Impact factor: 14.919

8.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

9.  Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation.

Authors:  Lu Long; Xudong Yang; Mark Southwood; Junyu Lu; Stefan J Marciniak; Benjamin J Dunmore; Nicholas W Morrell
Journal:  Circ Res       Date:  2013-02-27       Impact factor: 17.367

10.  Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2.

Authors:  Paola Caruso; Benjamin J Dunmore; Kenny Schlosser; Sandra Schoors; Claudia Dos Santos; Carol Perez-Iratxeta; Jessie R Lavoie; Hui Zhang; Lu Long; Amanda R Flockton; Maria G Frid; Paul D Upton; Angelo D'Alessandro; Charaka Hadinnapola; Fedir N Kiskin; Mohamad Taha; Liam A Hurst; Mark L Ormiston; Akiko Hata; Kurt R Stenmark; Peter Carmeliet; Duncan J Stewart; Nicholas W Morrell
Journal:  Circulation       Date:  2017-09-26       Impact factor: 29.690

View more
  6 in total

1.  The cancer hypothesis of pulmonary arterial hypertension: the next ten years.

Authors:  David Condon; Stuti Agarwal; Ananya Chakraborty; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-18       Impact factor: 5.464

Review 2.  Endothelial Senescence: A New Age in Pulmonary Hypertension.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  Circ Res       Date:  2022-03-17       Impact factor: 17.367

Review 3.  The Landscape of Noncoding RNA in Pulmonary Hypertension.

Authors:  Lin Deng; Xiaofeng Han; Ziping Wang; Xiaowei Nie; Jinsong Bian
Journal:  Biomolecules       Date:  2022-06-07

Review 4.  Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.

Authors:  Kurt W Prins; Thenappan Thenappan; E Kenneth Weir; Rajat Kalra; Marc Pritzker; Stephen L Archer
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

5.  Increased Lung Uric Acid Deteriorates Pulmonary Arterial Hypertension.

Authors:  Takanori Watanabe; Mariko Ishikawa; Kohtaro Abe; Tomohito Ishikawa; Satomi Imakiire; Kohei Masaki; Kazuya Hosokawa; Tomoko Fukuuchi; Kiyoko Kaneko; Toshio Ohtsubo; Mayumi Hirano; Katsuya Hirano; Hiroyuki Tsutsui
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

Review 6.  Perivascular Inflammation in Pulmonary Arterial Hypertension.

Authors:  Yijie Hu; Leon Chi; Wolfgang M Kuebler; Neil M Goldenberg
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.